Compare ENTA & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | EU |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.3M | 464.5M |
| IPO Year | 2012 | 2011 |
| Metric | ENTA | EU |
|---|---|---|
| Price | $12.96 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $20.40 | $4.00 |
| AVG Volume (30 Days) | 155.3K | ★ 3.1M |
| Earning Date | 01-01-0001 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | $58,334,000.00 |
| Revenue This Year | $5.91 | $17.41 |
| Revenue Next Year | N/A | $95.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.48 | ★ 163.38 |
| 52 Week Low | $4.09 | $1.01 |
| 52 Week High | $17.15 | $4.19 |
| Indicator | ENTA | EU |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 35.50 |
| Support Level | $12.09 | N/A |
| Resistance Level | $15.52 | $2.83 |
| Average True Range (ATR) | 0.81 | 0.17 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 4.86 | 21.08 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.